Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 03, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership changes within a specific employee fund and does not contain financial performance data.
Material Changes
The only material change disclosed is a reduction in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 18,406,628 ADRs
- New Holding: 18,366,834 ADRs
- Change Date: September 29, 2005
- Average Price: $50.67
The change resulted from a movement in the fund. Two directors, Dr J P Garnier and Dr T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction notification.
Investor Verification Points
- Verify the impact of the fund movement on the total share count held by the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr J P Garnier and Dr T Yamada in the fund's holdings.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.